Pemigatinib, the first FGFR1/2/3 selective inhibitor received accelerated FDA approval for patients carrying FGFR2 fusion/rearrangement in cholangiocarcinoma (13). This evidence concerns the gene FGFR2 and cholangiocarcinoma.